Novogen has developed a technology platform based on synthetic isoflavones that promises compounds which can kill cancer cells without harming healthy cells. [ + ]

COH, CSL, RMD, Pharmaxis, Sonic Healthcare, Avexa, Cellestis [ + ]

Positive data from Pharmaxis’ Phase III trial in cystic fibrosis [ + ]

Research Australia has published 'Trends in Health and Medical Research Funding', a statistical overview of expenditure on health and medical research by government, industry and philanthropy.

Brisbane biotech Implicit Bioscience has developed a business model unusual in Australia: it aims to return money to investors. [ + ]

Melbourne agbiotech Hexima has been making waves with its fungal and insect-resistance technology and a tasty deal with DuPont. [ + ]

Biota, CSL, Hexima, Alchemia, Mesoblast [ + ]

Mesoblast approved for Phase II trail for cervical spine fusion [ + ]

Prima BioMed applies for IND for CVac, raises cash [ + ]

Scientific equipment and consumables company Biolab has been aquired by Thermo Fisher Scientific.

With the discovery of a potentially key gene in the cell senescence process, Professor Jenny Gamble is looking at the role of senescence in vascular cells. [ + ]

“Walking seal” fossil sheds light on land-to-sea transition and pinniped evolution [ + ]

Biota, Circadian, Clinuvel, Cochlear, Pharmaxis, Diversa [ + ]

UK taxes rich, spends on tech investment fund [ + ]

Genetic Technologies, Circadian, Bionomics, Ambri, Hexima, LCT, Pharmaxis, Cellestis, AIC [ + ]